WT Microelectronics Co., Ltd. 3036

DEERFIELD, Ill., October 01, 2026--Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth and leave solutions, today announced its acquisition of Abett, a healthcare and benefits data technology company, that acts as a data infrastructure layer for Fortune 500 employers and their benefits vendors.

BILLERICA, Mass., October 01, 2026--Entegris, Inc. (NASDAQ: ENTG), will release its financial results for the third quarter of 2026, before the opening of the market on Thursday, October 29, 2026. A teleconference with management is scheduled for the same day at 8:00am ET.

Memory chips maker Micron (NASDAQ:MU) reported calendar Q3 2026 (fiscal Q4 2026) results exceeding the market’s revenue expectations, with sales up 379% year on year to $54.23 billion. On top of that, next quarter’s revenue guidance ($61.5 billion at the midpoint) was surprisingly good and 6.8% above what analysts were expecting. Its non-GAAP profit of $33.42 per share was 5% above analysts’ consensus estimates.

The company is making progress in an important area.

Synopsys (SNPS) is starting to position itself as a key player in the AI boom: At its investor day, the chip designer announced deals with both OpenAI (OPAI.PVT) and Amazon (AMZN). Synopsys CEO and president, Sassine Ghazi, sits down with Yahoo Finance anchor Julie Hyman to discuss the company's new partnerships.

Synopsys stock rose after the company's investor day presentation focused on growth from AI-assisted chip design tools.

One firm has a more tempered view of how much room this geothermal stock can run.

GE Vernova and Brookfield Renewable will benefit from Google's latest nuclear deal.

Is a stock market supercycle underway? John Pocorobba breaks down how millennial demographics and AI could propel the market through 2035.

Micron Technology delivered a sizable beat-and-raise earnings report, but investors needed time to appreciate the news.

St. Louis, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE: ESE) today announced that it has completed the acquisition of the Megger Group Limited (Megger) business of TBG AG (TBG). Under the terms of the transaction, TBG has agreed to certain lock-up provisions with respect to its equity ownership in ESCO common stock and has nomination rights for one seat on ESCO’s Board of Directors. The acquisition of Megger supports ESCO’s long-term objective of expanding our leadership posit

SEATTLE, October 01, 2026--Impinj to Announce Third-Quarter 2026 Financial Results

The IBM (NYSE: IBM) board of directors has elected Frank Baker to the board, effective October 1, 2026.

The company is constantly thinking big.

The fair value estimate for Hewlett Packard Enterprise has shifted from US$65.56 to US$68.08, a modest change that still matters if you are tracking valuation closely. This tweak reflects a divided analyst view, with supportive commentary pointing to strong server, cloud and AI orders, and more cautious voices focusing on networking supply constraints and the sharp share price move earlier in 2026. As you read on, you will see how to follow this evolving Hewlett Packard Enterprise narrative...

Bond markets have been hit hard, with the US 10 year Treasury yield at its highest level since 2002, which raises the hurdle for every risk asset you consider. Higher yields punish weaker balance sheets. They also push investors to look for businesses that feel essential rather than optional. Cybersecurity fits that bill. This article breaks down 3 US listed security stocks from our screener with healthier financial profiles. The three cybersecurity stocks below are a sample from our broader...

In September 2026, Atlassian Corporation (NasdaqGS: TEAM) was removed from the FTSE All-World Index (USD), even as it reported strong multi-year revenue and billings growth supported by high gross margins and an expanding contract pipeline. This combination of index exclusion and underlying operating strength highlights how benchmark changes can diverge from a company’s competitive position and business momentum. Next, we’ll explore how Atlassian’s robust revenue and billings growth shapes...

Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutinib could become the first high efficacy oral BTK inhibitor targeting both relapse control and disability progression in MS. The FDA's priority review for fenebrutinib in relapsing and primary progressive MS...